HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price

AnaptysBio (NASDAQ:ANAB) had its price target lowered by stock analysts at HC Wainwright from $55.00 to $52.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 141.97% from the company’s previous close.

A number of other analysts also recently weighed in on ANAB. UBS Group increased their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Guggenheim increased their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Wednesday. Finally, Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.45.

AnaptysBio Stock Down 3.2 %

AnaptysBio stock opened at $21.49 on Wednesday. The business has a 50 day moving average of $33.00 and a 200-day moving average of $29.83. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. On average, sell-side analysts anticipate that AnaptysBio will post -6.84 EPS for the current year.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other AnaptysBio news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were bought at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 in the last quarter. Insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio in the 1st quarter valued at about $38,000. Values First Advisors Inc. purchased a new stake in AnaptysBio in the 3rd quarter valued at about $49,000. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the last quarter. Headlands Technologies LLC increased its stake in AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.